Sanofi (SNY) said Wednesday the US Food and Drug Administration has approved the expanded use of Tzield to delay progression to stage 3 type 1 diabetes in children as young as one year of age with stage 2 disease from at least eight years.

Separately, Sanofi said the FDA has extended by up to three months its review of the company's application for a subcutaneous version of Sarclisa for multiple myeloma, setting a new decision date of July 23.

Sarclisa would be the first anticancer treatment administered via an on-body injector, if approved, the company said.